Q-omics provides the consensus-scored DQX1 profile across patient tissues and cancer cell-line models. DQX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DQX1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DQX1 RNA expression shows 15,073 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where DQX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DQX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DQX1 survival associations across molecular data types. DQX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DQX1 RNA expression–survival associations across cancer types. High DQX1 expression shows unfavorable associations in KIRC, ACC, UVM, KIRP, MESO and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DQX1 RNA expression.
This table summarizes DQX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DQX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DQX1 shows higher tumor expression in HNSC, LUSC, KIRP, BLCA, UCEC and BRCA. The HNSC box plot shows higher DQX1 RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with DQX1 in patient tissues and cancer cell lines. In patient samples, DQX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DQX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
